| 15.9 -1.74 (-9.86%) | 07-02 15:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.2 |
1-year : | 23.75 |
| Resists | First : | 15.58 |
Second : | 20.34 |
| Pivot price | 12.37  |
|||
| Supports | First : | 7.88 |
Second : | 6.56 |
| MAs | MA(5) : | 14.43 |
MA(20) : | 11.83 |
| MA(100) : | 9.74 |
MA(250) : | 6.45 |
|
| MACD | MACD : | 1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 77.2 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 20.34 | Low : | 2.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EKSO ] has closed above bottom band by 43.0%. Bollinger Bands are 134.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.81 - 11.87 | 11.87 - 11.91 |
| Low: | 11.26 - 11.32 | 11.32 - 11.37 |
| Close: | 11.7 - 11.81 | 11.81 - 11.89 |
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Fri, 16 Oct 2026
Ekso Bionics Holdings Releases Q1 2027 Financial Results - AlphaStreet
Wed, 07 Oct 2026
ChronoScale Director Resigns Following Ekso Bionics Divestiture - The Globe and Mail
Wed, 07 Oct 2026
Wandercraft acquires Ekso Bionics - HME News
Tue, 06 Oct 2026
A 51,626-unit stock grant vested immediately for a departing ChronoScale (CHRN) director. - Stock Titan
Fri, 02 Oct 2026
Pioneering Bay Area robotic exoskeleton company sells to French company after years of struggles - The Business Journals
Fri, 02 Oct 2026
Wandercraft Acquires Ekso Bionics to Expand Medical Exoskeleton Business - AI Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Information Technology Services
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 24.5 (%) |
| Held by Institutions | 26.7 (%) |
| Shares Short | 215 (K) |
| Shares Short P.Month | 268 (K) |
| EPS | -5.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.53 |
| Profit Margin | -91.4 % |
| Operating Margin | -119.8 % |
| Return on Assets (ttm) | -33.7 % |
| Return on Equity (ttm) | -107.7 % |
| Qtrly Rev. Growth | -38.3 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 3.59 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -2.31 |
| PEG Ratio | 0 |
| Price to Book value | 4.64 |
| Price to Sales | 3.28 |
| Price to Cash Flow | -3.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|